Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.46 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1160378 | 0.93 | PPARG (0.65) | PPARGRORCHDAC1HDAC6AGTR1 | |
| SCHEMBL1160011 | 0.93 | PPARG (0.65) | PPARGRORCHDAC1HDAC6AGTR1 | |
| SCHEMBL1160049 | 0.91 | PPARG (0.63) | PPARGRORCHDAC1HDAC6AGTR1 | |
| SCHEMBL27524161 | 0.90 | PPARG (0.62) | PPARGRORCHDAC1HDAC6PTPN1 | |
| SCHEMBL1160276 | 0.90 | PPARG (0.62) | PPARGRORCHDAC1HDAC6AGTR1 | |
| SCHEMBL1160409 | 0.90 | PPARG (0.59) | PPARGRORCHDAC1HDAC6AGTR1 | |
| SCHEMBL7594791 | 0.90 | PPARG (0.61) | PPARGRORCHDAC1HDAC6PTPN1 | |
| SCHEMBL7650594 | 0.89 | PPARG (0.78) | PPARGRORCHDAC1HDAC6AGTR1 | |
| SCHEMBL1178528 | 0.86 | PPARG (0.59) | PPARGRORCHDAC1HDAC6AGTR1 | |
| SCHEMBL1160232 | 0.85 | PPARG (0.78) | PPARGRORCHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024692-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | AESTUS THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-8563589-B2 | Methods of treating neuropathic pain with benzimidazole derivative agonists of PPARgamma | SAMEEVE CORP | 2013-10-22 | — | — | US | disclosed |
| EP-2459192-A1 | METHODS OF TREATING NEUROPATHIC PAIN WITH BENZIMIDAZOLE DERIVATIVE AGONISTS OF PPARGAMMA | Aestus Therapeutics, Inc. (US) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011014600-A1 | METHODS OF TREATING NEUROPATHIC PAIN WITH BENZIMIDAZOLE DERIVATIVE AGONISTS OF PPARGAMMA | AESTUS THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110028527-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | AESTUS THERAPEUTICS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | PPARG 1181/4885RORC 2268/4885HDAC1 222/4885 |
| US-20140024692-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | PPARG, PPARA, PPARD | PPARG 1/4885RORC 535/4885HDAC1 368/4885 |
| US-20110028527-A1 | Methods of Treating Neuropathic Pain with Benzimidazole Derivative Agonists of PPARgamma | PPARG, PPARA, PPARD | PPARG 1/4885RORC 535/4885HDAC1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.